USA - NASDAQ:CYRX - US2290503075 - Common Stock
The current stock price of CYRX is 10.01 USD. In the past month the price increased by 12.85%. In the past year, price increased by 32.58%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 24.11 | 199.33B | ||
DHR | DANAHER CORP | 27.37 | 147.58B | ||
BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 139.26 | 45.42B | ||
A | AGILENT TECHNOLOGIES INC | 25.62 | 39.59B | ||
IQV | IQVIA HOLDINGS INC | 17.71 | 34.53B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 31.88 | 26.86B | ||
WAT | WATERS CORP | 27.18 | 19.79B | ||
WST | WEST PHARMACEUTICAL SERVICES | 37.78 | 18.91B | ||
TEM | TEMPUS AI INC | N/A | 15.97B | ||
ICLR | ICON PLC | 14.2 | 14.61B | ||
MEDP | MEDPACE HOLDINGS INC | 38.24 | 14.45B | ||
ILMN | ILLUMINA INC | 22.36 | 14.29B |
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. The company is headquartered in Brentwood, Tennessee and currently employs 1,090 full-time employees. The company went IPO on 2015-07-24. The firm supports biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products. Its integrated supply chain platform includes the Cryoportal Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems. The firm's segments include Life Sciences Services and Life Sciences Products. The firm's Life Sciences Services segment provides cryogenic biostorage within the life science industry through direct sales. Its Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network.
CRYOPORT INC
112 Westwood Place, Suite 350
Brentwood TENNESSEE 37027 US
CEO: Jerrell W. Shelton
Employees: 1098
Phone: 19492321900
The current stock price of CYRX is 10.01 USD. The price increased by 7.4% in the last trading session.
The exchange symbol of CRYOPORT INC is CYRX and it is listed on the Nasdaq exchange.
CYRX stock is listed on the Nasdaq exchange.
15 analysts have analysed CYRX and the average price target is 12.92 USD. This implies a price increase of 29.07% is expected in the next year compared to the current price of 10.01. Check the CRYOPORT INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CRYOPORT INC (CYRX) has a market capitalization of 501.20M USD. This makes CYRX a Small Cap stock.
CRYOPORT INC (CYRX) currently has 1098 employees.
CRYOPORT INC (CYRX) has a support level at 9.46 and a resistance level at 10.13. Check the full technical report for a detailed analysis of CYRX support and resistance levels.
The Revenue of CRYOPORT INC (CYRX) is expected to decline by -24.8% in the next year. Check the estimates tab for more information on the CYRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CYRX does not pay a dividend.
CRYOPORT INC (CYRX) will report earnings on 2025-11-06, after the market close.
The PE ratio for CRYOPORT INC (CYRX) is 7.53. This is based on the reported non-GAAP earnings per share of 1.33 and the current share price of 10.01 USD. Check the full fundamental report for a full analysis of the valuation metrics for CYRX.
The outstanding short interest for CRYOPORT INC (CYRX) is 5.31% of its float. Check the ownership tab for more information on the CYRX short interest.
ChartMill assigns a technical rating of 8 / 10 to CYRX. When comparing the yearly performance of all stocks, CYRX is one of the better performing stocks in the market, outperforming 88.3% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to CYRX. While CYRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CYRX reported a non-GAAP Earnings per Share(EPS) of 1.33. The EPS increased by 156.84% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 33.22% | ||
ROA | 8.7% | ||
ROE | 13.06% | ||
Debt/Equity | 0.36 |
15 analysts have analysed CYRX and the average price target is 12.92 USD. This implies a price increase of 29.07% is expected in the next year compared to the current price of 10.01.
For the next year, analysts expect an EPS growth of 81.14% and a revenue growth -24.8% for CYRX